Welcome to our dedicated page for Viracta Therapeutics news (Ticker: VIRX), a resource for investors and traders seeking the latest updates and insights on Viracta Therapeutics stock.
Viracta Therapeutics, Inc. (symbol: VIRX) is a precision oncology company dedicated to developing innovative therapies targeting virus-associated cancers, particularly those linked to the Epstein-Barr Virus (EBV). The company is pioneering a proprietary viral gene activation therapy aimed at treating serious virus-associated diseases.
Viracta is currently conducting three clinical trials for its combination product candidate, designed as a potential treatment for relapsed/refractory EBV-positive lymphoma. This product candidate integrates nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), with valganciclovir, an FDA-approved antiviral drug used to treat cytomegalovirus (CMV) infections.
The company’s research focuses on advancing its Nana-val (nanatinostat and valganciclovir) therapy through various phases of clinical trials. Recent projects include the Phase 1b/2 study of Nana-val in recurrent/metastatic EBV+ nasopharyngeal carcinoma (NPC) and other EBV+ solid tumors.
Viracta Therapeutics is committed to delivering breakthrough treatments that address the unmet medical needs of patients with virus-associated malignancies. The company continues to establish partnerships and collaborations to enhance its research and development capabilities, ensuring a robust pipeline of innovative therapies.
For the latest updates and further information, please visit www.viracta.com.
Viracta Therapeutics (Nasdaq: VIRX) reported third quarter 2022 results showing a net loss of approximately $17.7 million, or $0.47 per share, up from $14.9 million, or $0.40 per share, in Q3 2021. The company has cash and equivalents of $77.1 million, sufficient to fund operations into mid-2024. Key developments include the initiation of the pivotal NAVAL-1 trial for Nana-val in EBV-positive lymphoma across 50 sites and a successful third dose level enrollment in the Phase 1b/2 trial for EBV-positive solid tumors. An update on trial advancements is expected in early 2023.
Viracta Therapeutics, Inc. (Nasdaq: VIRX) has announced its leadership will present at four investor conferences in November 2022. Presentations include:
- Stifel 2022 Healthcare Conference on November 15, 2022, at 3:35 PM ET
- 13th Annual Jefferies London Healthcare Conference on November 16, 2022, at 5:35 PM GMT / 12:35 PM ET
- Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 10:30 AM ET
- 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 1:50 PM ET
Webcasts will be available on their website.
Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced the appointment of Mark Rothera as President and CEO, with an accompanying stock option grant of 1,375,000 shares. This option vests over four years, with 25% vested after one year and the remaining 75% vesting monthly. The exercise price is $5.21 per share, matching the stock's closing price on September 19, 2022. The award is part of Viracta's 2021 Inducement Equity Incentive Plan, intended for new employees as an inducement for their employment.
Viracta Therapeutics has appointed Mark Rothera as President and Chief Executive Officer, effective September 19, 2022. Ivor Royston, the founding CEO, will remain on the Board of Directors. Rothera brings over 30 years of biopharmaceutical experience and aims to advance the company's drug, Nana-val, towards clinical development and marketing approval. This transition follows Rothera's notable achievements in prior roles, including increasing market capitalization and securing significant financing. Viracta focuses on therapies for Epstein-Barr virus-associated malignancies.
The European Commission has granted orphan drug designation (ODD) for Nana-val, a combination therapy of nanatinostat and valganciclovir, to treat peripheral T-cell lymphoma (PTCL). This designation recognizes the high unmet medical need and positions Nana-val as the fifth globally to receive ODD. Previously, Nana-val received ODD from the FDA for various T-cell lymphomas. Following a Phase 1b/2 trial, the ongoing global Phase 2 NAVAL-1 trial is focusing on relapsed/refractory Epstein-Barr virus-positive lymphomas and aims to enroll approximately 140 patients.
Viracta Therapeutics (Nasdaq: VIRX) announced that its Chief Scientific Officer, Ayman Elguindy, has been elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases. This recognition highlights Dr. Elguindy's expertise in virus-associated cancers, and his commitment to advancing research in this field. Viracta focuses on precision oncology, with its lead product candidate, Nana-val, undergoing multiple clinical trials for treating EBV-positive malignancies. This move could enhance the company's reputation and foster further research collaborations.
Viracta Therapeutics (Nasdaq: VIRX) has appointed Jane Chung, R.Ph., to its Board of Directors. Chung brings over 20 years of experience in oncology and commercial leadership, having held key roles at companies like Sutro Biopharma and AstraZeneca. Her expertise is anticipated to enhance Viracta's strategic direction as it advances its pivotal NAVAL-1 study for Epstein-Barr virus-positive lymphoma and a Phase 1b/2 trial for advanced EBV+ solid tumors. Chung expressed enthusiasm for assisting the company's management in achieving its objectives.
Viracta Therapeutics (Nasdaq: VIRX) announced progress in its Nana-val clinical trials for EBV-positive lymphoma and solid tumors, with key data expected in Q4 2022. As of June 30, 2022, the company reported cash reserves of $83.1 million, projected to fund operations through mid-2024. The Phase 1b/2 trial has advanced to a second dose escalation cohort, while the NAVAL-1 trial now allows enrollment of second-line peripheral T-cell lymphoma patients. Despite a net loss of $10.6 million for Q2 2022, the company remains committed to its clinical milestones.
Viracta Therapeutics (Nasdaq: VIRX) announced that Dr. Ivor Royston, its President and CEO, received the Biotechnology Heritage Award from the Science History Institute on June 13, 2022, at the BIO International Convention in San Diego.
This award recognizes individuals who contribute significantly to biotechnology. Dr. Royston highlighted his commitment to advancing therapeutics for virus-associated cancers, particularly through the company's lead product, Nana-val, targeting Epstein-Barr virus (EBV)-associated malignancies, which constitute nearly 2% of global cancers.
Viracta Therapeutics (Nasdaq: VIRX) announced significant advancements in its ongoing Phase 1b/2 trial of Nana-val for patients with EBV-positive solid tumors. The Safety Monitoring Committee approved the escalation to the second dose cohort after observing no dose-limiting toxicities to date. The trial focuses on patients with recurrent or metastatic nasopharyngeal cancer. Preliminary safety and efficacy data are expected by the second half of 2022. Additionally, a poster presentation summarizing the trial's design will occur at the ASCO Annual Meeting on June 6, 2022.
FAQ
What is the current stock price of Viracta Therapeutics (VIRX)?
What is the market cap of Viracta Therapeutics (VIRX)?
What does Viracta Therapeutics, Inc. specialize in?
What is nanatinostat?
What is valganciclovir used for?
What are the current projects of Viracta Therapeutics?
What is the Nana-val therapy?
Where can I find more information about Viracta Therapeutics?
Who is the contact person for investor relations at Viracta?
What types of cancers is Viracta targeting?
How does Viracta's viral gene activation therapy work?
What is the significance of the Phase 1b/2 study of Nana-val?
